Author argues Novo Nordisk is the biggest value play of 2026, citing its newly released oral GLP-1 beating Eli Lilly to market and a 15 PE valuation.
NVO — LONG The author claims Novo Nordisk is the biggest value play of 2026 because its new oral GLP-1 launched before Eli Lilly's competing product, positioning NVO to dominate the market. The mechanism is that an earlier oral entrant captures market share in the obesity/diabetes drug market, driving growth. The stated catalyst is the oral launch and the valuation support is a 15 PE, which the author sees as leaving massive room to grow. No specific risk is stated.
With their new oral that just released before Eli Lilly, NVO is set to dominate the market. This is the most obvious value play of the year with massive room to grow still, treating at only 15 PE
This Reddit post, published January 09, 2026, features u/Chevyimpala2000 discussing NVO. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Chevyimpala2000 · Tickers: NVO